newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus

- Phase 3 AZURE-1 enrollment complete - Phase 3 AZURE-4 screening complete - Topline AZURE-1 and AZURE-4 results expected in 2H 2026 - AZURE-1 and AZURE-4 to form the basis of Mirum's U.S. BLA Submission Mirum